The Role of miRNAs in Cisplatin-Resistant HeLa Cells.

Yubo Yang,Cuihong Dai,Zhipeng Cai,Aiju Hou,Dayou Cheng,Dechang Xu

DOI: https://doi.org/10.1007/978-3-319-19048-8_30

2015-01-01

Abstract:Chemotherapy is the main strategy in the treatment of cancer, however, the development of drug-resistance is the obstacle in long-term treatment of cervical cancer. Cisplatin is one of the most common drugs used in cancer therapy. Recently, accumulating evidence suggests that miRNAs are involved in various bioactivities in oncogenesis. It is not unexpected that miRNAs play a key role in acquiring of drug-resistance in the progression of tumor. In this study, we induced and maintained four levels of cisplatin-resistant HeLa cell lines (HeLa/CR1, HeLa/CR2, HeLa/CR3 and HeLa/CR4). According to the previous studies and exiting evidence, we selected five miRNAs (miR-183, miR-182, miR-30a, miR-15b and miR-16) and their potential target mRNAs as our research targets. The real-time RT-PCR was used to detect the relative expression of miRNAs and their mRNAs. The results show that miR-182 and miR-15b were up-regulated in resistant cell lines while miR-30a was significantly down-regulated. At the same time, the targets they regulated are related to the drug-resistance. The expression alteration of selected miRNAs in resistant cell lines compared to their parent HeLa cell line suggests that HeLa cell drug resistance is associated with distinct miRNAs, which indicates that miRNAs may be one of the therapy targets in the treatment of cervical cancer by sensitizing cell to chemotherapy.